- $485.88m
- $260.49m
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable
U.S. STOCKS ON THE MOVE-General Mills, Meta, Lockheed Martin
U.S. STOCKS ON THE MOVE-MSC Industrial, Nike, Bloom Energy
Brief: Neurogene Sets Pricing For $125 Million Public Offering
Neurogene down after $125 mln equity raise
Brief: Neurogene Inc Files For Offering Of Common Stock, Pre-Funded Warrants To Buy Common Stock Size Not Disclosed - SEC Filing
Neurogene drops after starting equity offering
Brief: Neurogene Inc. Announces Proposed Public Offering
Neurogene Q1 net loss widens on higher R&D costs
Brief: Neurogene Q1 Operating Expenses USD 33.349 Million
Brief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Neurogene Appoints Christy Shafer As Chief Commercial Officer And Christine Mikail, J.D., To Board Of Directors
Neurogene full yr net loss widens on higher R&D costs
Brief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Talen Energy, Applied Optoelectronics, oil companies
U.S. STOCKS ON THE MOVE-Oil companies, Arlo Technologies, AES